CRISPR Therapeutics AG - Common Shares (CRSP)
CRSP moved a median of +0.10% 30 minutes after news, and -0.17% by the close. How CRSP actually reacts to news — the realized, point-in-time move the market made, measured across 291 labeled events over the last three years with zero look-ahead.
CRSP’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.17% | 46% | 290 |
| 30-min | +0.10% | 53% | 290 |
| 60-min | +0.10% | 51% | 290 |
| to close | -0.17% | 45% | 290 |
| Middle 50% of CRSP reactions | -1.52% to +1.26% |
|---|---|
| Median reaction (30-min) | +0.10% |
| Measured reactions | 291 |
Half of all CRISPR Therapeutics AG - Common Shares news events land between -1.52% and +1.26% at 30 minutes.
Reaction stats as of 2026-08-31. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CRSP reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 17 | +0.92% | 65% | +1.58% |
| Analyst downgrades | 10 | -0.10% | 10% | +0.37% |
| Coverage initiations | 16 | +0.72% | 63% | +0.58% |
| Rating reiterations | 157 | -0.05% | 48% | +0.37% |
| Price-target raises | 21 | +0.34% | 62% | +1.25% |
| Price-target cuts | 32 | -0.18% | 44% | +0.10% |
Last 3 years, pulled 2026-08-31. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how CRSP ranks against every other measured name →
That’s how CRSP usually reacts — get an email when it moves on news →Email me when CRSP moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CRSP's baseline. Nothing else.
Recent CRSP events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference | Press release | GlobeNewswire | -2.08% | +0.61% | |
| CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026 | Press release | GlobeNewswire | +1.91% | +0.65% | |
| CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +2.58% | +5.09% | |
| Form 10-Q CRISPR Therapeutics AG For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.58% | +5.09% | |
| Form 8-K CRISPR Therapeutics AG For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | +2.58% | +5.09% | |
| Form S-8 CRISPR Therapeutics AG | SEC filing · Form S-8 | SEC EDGAR | -1.39% | -6.90% | |
| Form 8-K CRISPR Therapeutics AG For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | -1.39% | -6.90% | |
| CRISPR Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -1.24% | +6.30% | |
| CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference | Press release | GlobeNewswire | -0.26% | +3.92% | |
| CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | +1.29% | -0.23% | |
| Form 10-Q CRISPR Therapeutics AG For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.29% | -0.23% | |
| Form 8-K CRISPR Therapeutics AG For: May 04 | SEC filing · Form 8-K | SEC EDGAR | +1.29% | -0.23% | |
| Form ARS CRISPR Therapeutics AG For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.80% | -3.34% | |
| Form DEF 14A CRISPR Therapeutics AG For: Jun 04 | SEC filing · Form DEF | SEC EDGAR | -0.80% | -3.34% | |
| Form DEFA14A CRISPR Therapeutics AG | SEC filing · Form DEFA14A | SEC EDGAR | -0.80% | -3.34% | |
| CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference | Press release | GlobeNewswire | +0.01% | +2.39% | |
| Form PRE 14A CRISPR Therapeutics AG For: Jun 04 | SEC filing · Form PRE | SEC EDGAR | +0.92% | -1.11% | |
| Form 8-K CRISPR Therapeutics AG For: Mar 16 | SEC filing · Form 8-K | SEC EDGAR | +0.41% | +2.43% | |
| CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering | Press release | GlobeNewswire | -0.64% | -4.00% | |
| Form 8-K CRISPR Therapeutics AG For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | -0.64% | -4.00% | |
| CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering | Press release | GlobeNewswire | +1.80% | -2.06% | |
| CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | +4.76% | +6.70% | |
| Form 10-K CRISPR Therapeutics AG For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +4.76% | +6.70% | |
| Form 8-K CRISPR Therapeutics AG For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | +4.76% | +6.70% | |
| CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones | Press release | GlobeNewswire | -0.65% | +2.41% | |
| Form 8-K CRISPR Therapeutics AG For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -0.65% | +2.41% | |
| CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +1.26% | +2.47% | |
| Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize | Press release | PR Newswire | -0.21% | +1.78% | |
| CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies | Press release | GlobeNewswire | +0.69% | +3.41% | |
| CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results | Press release | GlobeNewswire | -1.01% | -6.22% | |
| Form 10-Q CRISPR Therapeutics AG For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.01% | -6.22% | |
| Form 8-K CRISPR Therapeutics AG For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | -1.01% | -6.22% | |
| CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering | Press release | GlobeNewswire | -1.01% | -6.22% | |
| Form 8-K CRISPR Therapeutics AG For: Oct 15 | SEC filing · Form 8-K | SEC EDGAR | +0.59% | -2.24% | |
| CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform | Press release | GlobeNewswire | -1.70% | -5.47% | |
| Australia’s Largest University Establishes ‘Monash Boston Hub’ to Accelerate Global Biotech Partnerships and Licensing | Press release | Business Wire | -0.74% | +8.27% | |
| CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress | Press release | GlobeNewswire | +1.69% | +2.18% | |
| CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | Press release | GlobeNewswire | -1.76% | -0.40% | |
| Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises | Press release | Canada Newswire | +0.22% | +3.66% | |
| CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025 | Press release | GlobeNewswire | +0.27% | -3.47% | |
| CRISPR Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +2.23% | +3.27% | |
| CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results | Press release | GlobeNewswire | -2.49% | +2.94% | |
| Form 10-Q CRISPR Therapeutics AG For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.49% | +2.94% | |
| Form 8-K CRISPR Therapeutics AG For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | -2.49% | +2.94% | |
| Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers | Press release | Canada Newswire | +1.97% | +7.48% | |
| CRISPR Therapeutics Named to TIME’s Most Influential Companies List of 2025 | Press release | GlobeNewswire | -0.69% | +1.76% | |
| CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline | Press release | GlobeNewswire | -2.27% | -0.79% | |
| Form 8-K CRISPR Therapeutics AG For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | -2.27% | -0.79% | |
| Form 8-K CRISPR Therapeutics AG For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | +0.82% | +0.16% | |
| CRISPR Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -4.82% | -1.55% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CRSP section they belong to.
Where else CRSP is measured.
CRSP earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Trinity Biotech plc - American Depositary Shares (TRIB) | 293 | -0.13% | 42% |
| Merus N.V. - Common Shares (MRUS) | 292 | +0.03% | 54% |
| Seres Therapeutics, Inc. (MCRB) | 290 | -0.23% | 46% |
| Adicet Bio, Inc. (ACET) | 288 | -0.80% | 36% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is CRISPR Therapeutics AG - Common Shares's median reaction calculated?
Every labeled CRSP news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 291 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 53% of CRSP's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-31.
Does CRSP's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.